Daliresp 250 ug/1
roflumilast · TABLET · AstraZeneca Pharmaceuticals LP
No Recall History
Plain English
Daliresp is a tablet containing roflumilast at 250 ug/1, taken oral. Manufactured by AstraZeneca Pharmaceuticals LP.
Key Facts
- Brand Name
- Daliresp
- Generic Name
- roflumilast
- NDC Code (Product)
0310-0088- Manufacturer
- AstraZeneca Pharmaceuticals LP
- Strength
- 250 ug/1
- Dosage Form
- TABLET
- Route
- ORAL
- Marketing Status
- Application #
- NDA022522
- Drug Class
- Phosphodiesterase 4 Inhibitor [EPC]
- Marketing Start
- 07/01/2015
Recall History
No Recall HistorySide Effects Reported to FDA
FDA FAERS database · These are reported events, not confirmed side effects
dyspnoea1,020 reports
death735 reports
chronic obstructive pulmonary disease643 reports
diarrhoea521 reports
nausea449 reports
pneumonia449 reports
weight decreased435 reports
headache349 reports
cough346 reports
off label use297 reports
Frequently Asked Questions
What is Daliresp used for?
Daliresp contains roflumilast. It is a tablet taken oral. Consult your doctor for specific uses.
Is Daliresp a controlled substance?
Daliresp is not classified as a controlled substance by the DEA.
What is the generic name for Daliresp?
The generic name for Daliresp is roflumilast. There are 12 other brand versions of roflumilast.
What is the NDC code for Daliresp 250 ug/1?
The NDC (National Drug Code) for Daliresp 250 ug/1 is 0310-0088, listed by AstraZeneca Pharmaceuticals LP.